<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04405999</url>
  </required_header>
  <id_info>
    <org_study_id>05-20-02-ะก</org_study_id>
    <nct_id>NCT04405999</nct_id>
  </id_info>
  <brief_title>Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease</brief_title>
  <official_title>Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial of the efficacy and safety evaluation of oral&#xD;
      administration of Bromhexine hydrochloride for the prevention of SARS-CoV-2 infection and&#xD;
      COVID-19 disease in medical personnel assisting patients with a new coronavirus disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate the oral administration of Bromhexine hydrochloride for the&#xD;
      prevention of SARS-CoV-2 infection and COVID-19 disease in medical personnel assisting&#xD;
      patients with a new coronavirus disease. The aim of the study is to determine the preventive&#xD;
      role of this drug in the framework of reducing the incidence of coronavirus infection in risk&#xD;
      groups (medical personnel). Several studies show, that the acute respiratory syndrome&#xD;
      coronavirus SARS-CoV uses endosomal cysteine proteases cathepsin B and L (CatB/L) and the&#xD;
      transmembrane protease serine type 2 (TMPRSS2) for the priming of the viral S-protein. The&#xD;
      new coronavirus SARS-CoV-2 penetrates into alveolar epithelial type two cells through a&#xD;
      similar mechanism. In detail, viral S-protein binds to pneumocyte angiotensin-converting&#xD;
      enzyme 2 (ACE2) and then undergoes cleaving by TMPRSS2 in S1- and S2-subunits. This leads to&#xD;
      the release of a fusion peptide, which allows the virus to enter the cell via endocytosis.&#xD;
      Therefore, the protease TMPRSS2 can serve as a target for pharmacological agents to prevent&#xD;
      the penetration of the SARS-CoV-2 into the cell. Bromhexine blocks the TMPRSS2 ability to&#xD;
      activate a zymogen precursor of tissue plasminogen activator in vitro. Interestingly, TMPRSS2&#xD;
      is blocked by much lower concentrations then required to inactivate other proteases in the&#xD;
      cell culture. However, these data cannot be simply extended to the clinical practice: whether&#xD;
      the concentration of bromhexine in the lung tissue of properly treated patients would be&#xD;
      enough to prevent the virus entry through the TMPRSS2-inactivation remains unclear. A&#xD;
      randomized study in people at risk for coronavirus infection will clarify the role of&#xD;
      Bromhexine hydrochloride as a prevention of this disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2020</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 9, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative Polymerase Chain Reaction (PCR)</measure>
    <time_frame>4 weeks after randomization</time_frame>
    <description>Number of Participants with Negative PCR of SARS-CoV-2 and The Absence of Clinical Manifestations of COVID-19 Infection in individuals taking Bromhexine hydrochloride 4 weeks after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Asymptomatic SARS-CoV-2 Infection</measure>
    <time_frame>14 days after last contact</time_frame>
    <description>Number of Participants with Asymptomatic SARS-CoV-2 Infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mild, Moderate and Severe COVID-19 Disease</measure>
    <time_frame>14 days after last contact</time_frame>
    <description>number of participants with mild, moderate and severe COVID-19 disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>14 days after last contact</time_frame>
    <description>Number of Participants with Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Increased Risk of SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Bromhexine hydrochloride Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromhexine Hydrochloride</intervention_name>
    <description>Medical personnel at risk for COVID-19 infection will receive study medication for 14 days</description>
    <arm_group_label>Bromhexine hydrochloride Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of 18 years or more;&#xD;
&#xD;
          2. Negative test (PCR) for SARS-CoV-2 infection;&#xD;
&#xD;
          3. The absence of clinical manifestations of a respiratory infection;&#xD;
&#xD;
          4. Contact with patients with laboratory and / or clinically confirmed SARS-CoV-2&#xD;
             infection;&#xD;
&#xD;
          5. Signed informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intolerance to Bromhexine hydrochloride;&#xD;
&#xD;
          2. Work out of contact with SARS-CoV-2 infection;&#xD;
&#xD;
          3. Non-compliance with the rules for the use of personal protective equipment when&#xD;
             working with SARS-CoV-2 infection (the rules for the use of personal protective&#xD;
             equipment in accordance with the recommendations of the Ministry of Health of Russia&#xD;
             and the internal orders of the Director General of Almazov NMRC, relevant to the dates&#xD;
             of research);&#xD;
&#xD;
          4. Pregnancy and the period of breastfeeding;&#xD;
&#xD;
          5. Other circumstances that the researcher considers inappropriate to participate in this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evgeny Mikhaylov, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Almazov National Medical Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <results_first_submitted>March 21, 2022</results_first_submitted>
  <results_first_submitted_qc>April 11, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2022</results_first_posted>
  <last_update_submitted>April 11, 2022</last_update_submitted>
  <last_update_submitted_qc>April 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromhexine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT04405999/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was performed via the institution's electronic communication system and via personal contacts with healthcare providers. Following a general notification via an institutional electronic system, one hundred and fifty healthcare providers were contacted personally and 50 persons were included.</recruitment_details>
      <pre_assignment_details>No subjects were excluded from the study before assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride&#xD;
Bromhexine Hydrochloride: Medical personnel at risk for COVID-19 infection will receive study medication for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bromhexine Hydrochloride Group</title>
          <description>medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride&#xD;
Bromhexine Hydrochloride: Medical personnel at risk for COVID-19 infection will receive study medication for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.7" spread="6.9"/>
                    <measurement group_id="B2" value="39.5" spread="8.2"/>
                    <measurement group_id="B3" value="40.6" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Negative Polymerase Chain Reaction (PCR)</title>
        <description>Number of Participants with Negative PCR of SARS-CoV-2 and The Absence of Clinical Manifestations of COVID-19 Infection in individuals taking Bromhexine hydrochloride 4 weeks after randomization.</description>
        <time_frame>4 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride&#xD;
Bromhexine Hydrochloride: Medical personnel at risk for COVID-19 infection will receive study medication for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Polymerase Chain Reaction (PCR)</title>
          <description>Number of Participants with Negative PCR of SARS-CoV-2 and The Absence of Clinical Manifestations of COVID-19 Infection in individuals taking Bromhexine hydrochloride 4 weeks after randomization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Asymptomatic SARS-CoV-2 Infection</title>
        <description>Number of Participants with Asymptomatic SARS-CoV-2 Infection</description>
        <time_frame>14 days after last contact</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride&#xD;
Bromhexine Hydrochloride: Medical personnel at risk for COVID-19 infection will receive study medication for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Asymptomatic SARS-CoV-2 Infection</title>
          <description>Number of Participants with Asymptomatic SARS-CoV-2 Infection</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mild, Moderate and Severe COVID-19 Disease</title>
        <description>number of participants with mild, moderate and severe COVID-19 disease</description>
        <time_frame>14 days after last contact</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride&#xD;
Bromhexine Hydrochloride: Medical personnel at risk for COVID-19 infection will receive study medication for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mild, Moderate and Severe COVID-19 Disease</title>
          <description>number of participants with mild, moderate and severe COVID-19 disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Number of Participants with Adverse Events</description>
        <time_frame>14 days after last contact</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride&#xD;
Bromhexine Hydrochloride: Medical personnel at risk for COVID-19 infection will receive study medication for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Number of Participants with Adverse Events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over 8 weeks.</time_frame>
      <desc>Overall number of participants affected by one or more Serious Adverse Events, for each arm/group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bromhexine Hydrochloride Group</title>
          <description>medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride&#xD;
Bromhexine Hydrochloride: Medical personnel at risk for COVID-19 infection will receive study medication for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cough</sub_title>
                <description>Transient cough without sequelae. Drug treatment was not interrupted.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flash hot</sub_title>
                <description>A short period of hot flashes at treatment initiation without sequelae. Treatment was not interrupted.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Evgeny Mikhaylov</name_or_title>
      <organization>Almazov National Medical Research Centre</organization>
      <phone>+7(812)7023764</phone>
      <email>e.mikhaylov@almazovcentre.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

